Skip to content
Pafolacianine
Cytalux (pafolacianine) is a small molecule pharmaceutical. Pafolacianine was first approved as Cytalux on 2021-11-29.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Cytalux
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pafolacianine sodium
Tradename
Company
Number
Date
Products
CYTALUXOn Target LaboratoriesN-214907 RX2021-11-29
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cytaluxNew Drug Application2022-01-31
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
PAFOLACIANINE SODIUM, CYTALUX, ON TARGET LABS
2028-11-29ODE-390
2026-11-29NCE
2025-12-16I-905
Patent Expiration
Patent
Expires
Flag
FDA Information
Pafolacianine Sodium, Cytalux, On Target Labs
92543412033-10-04DS, DP
90610572033-08-26DS, DPU-3291
93332702033-08-26DS, DPU-3291
93416292033-08-26DS, DP
97892082033-08-26DS, DPU-3291
108817472033-08-26DS, DPU-3291
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C56111——3
Lung neoplasmsD008175C34.90—11——2
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C802————2
Pituitary neoplasmsD0109111————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD002292————11
Stomach neoplasmsD013274EFO_0003897C16————11
Urinary bladder neoplasmsD001749C67————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePAFOLACIANINE
INNpafolacianine
Description
Pafolacianine, sold under the brand name Cytalux, is an optical imaging agent used in fluorescence-guided surgery. Pafolacianine is a fluorescent medication that binds to folate receptor (FR)-expressing cells.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1(C)C(/C=C/C2=C(Oc3ccc(C[C@H](NC(=O)c4ccc(NCc5cnc6nc(N)[nH]c(=O)c6n5)cc4)C(=O)[O-])cc3)/C(=C/C=C3\N(CCCCS(=O)(=O)[O-])c4ccc(S(=O)(=O)[O-])cc4C3(C)C)CCC2)=[N+](CCCCS(=O)(=O)[O-])c2ccc(S(=O)(=O)[O-])cc21.[H+].[H+].[H+].[H+]
Identifiers
PDB—
CAS-ID1628423-76-6
RxCUI—
ChEMBL IDCHEMBL4297412
ChEBI ID—
PubChem CID90479076
DrugBankDB15413
UNII IDF7BD3Z4X8L (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 39 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details